US20130024129A1 - Detecting chemical components from spectroscopic observations - Google Patents

Detecting chemical components from spectroscopic observations Download PDF

Info

Publication number
US20130024129A1
US20130024129A1 US13/625,707 US201213625707A US2013024129A1 US 20130024129 A1 US20130024129 A1 US 20130024129A1 US 201213625707 A US201213625707 A US 201213625707A US 2013024129 A1 US2013024129 A1 US 2013024129A1
Authority
US
United States
Prior art keywords
tissue
concentration
model
patient
tissue sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/625,707
Inventor
Steven E. Pav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nellcor Puritan Bennett LLC
Original Assignee
Nellcor Puritan Bennett LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nellcor Puritan Bennett LLC filed Critical Nellcor Puritan Bennett LLC
Priority to US13/625,707 priority Critical patent/US20130024129A1/en
Publication of US20130024129A1 publication Critical patent/US20130024129A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases

Definitions

  • the present disclosure relates generally to the field of spectroscopy and, more particularly, to a system and method of optimizing the processing spectroscopic data.
  • Spectroscopy may be employed to ascertain the existence and/or concentration of component chemicals in a sample.
  • a source may first send electromagnetic radiation through the sample.
  • the spectrum of electromagnetic radiation which passes through the sample may indicate the absorbance of the sample.
  • the presence and/or concentration of distinct chemicals may be detected by employing methods of spectrographic data processing.
  • the analysis includes modeling the underlying concentrations of chromophores in a sample from spectroscopic observations.
  • the most common method for estimating these chromophores concentrations includes applying a photon scattering and absorption model based solely on the Beer-Lambert Law and utilizing multiple linear regression techniques to approximate the chromophores concentrations.
  • the current methods may result in errors on the order of several percent. As such, a method and system for closer approximation of underlying concentrations of chromophores in a sample from spectroscopic observations is needed.
  • a method of processing spectrographic data may include transmitting an optical signal from an emitter to a sample, receiving the optical signal having passed through the sample at a detector, and analyzing the data associated with the received sample by numerically calculating an approximation of underlying concentrations of chromophores by applying a photon scattering and absorption model based on a mixed Beer-Lambert/Kohlrausch-Williams-Watts Model (KWW) for photon diffusion.
  • WW mixed Beer-Lambert/Kohlrausch-Williams-Watts Model
  • a method for using Kernel Partial Least Squares (KPLS) Regression to formulate a model to be used in conjunction with analyzing spectrographic data includes collecting a number of data samples of optical signals passed through a sample from an emitter to a detector, measuring an affine function of the concentrations of the components for each given sample, and performing a KPLS regression to find a model for estimating future spectroscopic data.
  • KPLS Kernel Partial Least Squares
  • FIG. 1 illustrates a perspective view of a pulse oximeter in accordance with an embodiment
  • FIG. 2 illustrates a simplified block diagram of a pulse oximeter in FIG. 1 , according to an embodiment
  • FIG. 3 illustrates a graph of diffuse reflectance of a sample area measured by the pulse oximeter in FIG. 1 , according to an embodiment.
  • the present disclosure is related to a photon scattering and absorption model which may be applied as an alternative to a strict application of the Beer-Lambert Law for estimation of the underlying concentrations of chromophores in a sample.
  • the photon scattering and absorption model may be based on Laplace and stable distributions which reveal that measurements in diffuse reflectance may follow a Beer-Lambert and Kohlrausch-Williams-Watts (KWW) product. This Beer-Lambert portion of the product may dominate in high absorption sample areas, while the KWW portion of the product may dominate in low absorption sample areas.
  • the medical device may be a pulse oximeter 100 .
  • the pulse oximeter 100 may include a monitor 102 .
  • the monitor 102 may be configured to display calculated parameters on a display 104 .
  • the display 104 may be integrated into the monitor 102 .
  • the monitor 102 may be configured to provide data via a port to a display (not shown) that is not integrated with the monitor 102 .
  • the display 104 may be configured to display computed physiological data including, for example, an oxygen saturation percentage, a pulse rate, and/or a plethysmographic waveform 106 .
  • the oxygen saturation percentage may be a functional arterial hemoglobin oxygen saturation measurement in units of percentage SpO 2
  • the pulse rate may indicate a patient's pulse rate in beats per minute.
  • the monitor 102 may also display information related to alarms, monitor settings, and/or signal quality via indicator lights 108 .
  • the monitor 102 may include a plurality of control inputs 110 .
  • the control inputs 110 may include fixed function keys, programmable function keys, and soft keys. Specifically, the control inputs 110 may correspond to soft key icons in the display 104 . Pressing control inputs 110 associated with, or adjacent to, an icon in the display may select a corresponding option.
  • the monitor 102 may also include a casing 118 . The casing 118 may aid in the protection of the internal elements of the monitor 102 from damage.
  • the monitor 102 may further include a sensor port 112 .
  • the sensor port 112 may allow for connection to an external sensor.
  • FIG. 1A illustrates a sensor 114 that may be used with the monitor 102 .
  • the sensor 114 may be communicatively coupled to the monitor 102 via a cable 116 which connects to the sensor port 112 .
  • the sensor 114 may be of a disposable or a non-disposable type.
  • the sensor 114 may obtain readings from a patient, which can be used by the monitor to calculate certain physiological characteristics such as the blood-oxygen saturation of hemoglobin in arterial blood, the volume of individual blood pulsations supplying the tissue, and/or the rate of blood pulsations corresponding to each heartbeat of a patient.
  • the sensor 114 and the monitor 102 may combine to form the pulse oximeter 100 .
  • the medical device may be the pulse oximeter 100 .
  • the pulse oximeter 100 may include a sensor 114 having one or more emitters 202 configured to transmit electromagnetic radiation, i.e., light, into the tissue of a patient 204 .
  • the emitter 202 may include a plurality of LEDs operating at discrete wavelengths, such as in the red and infrared portions of the electromagnetic radiation spectrum.
  • the emitter 202 may be a broad spectrum emitter, or it may include wavelengths for measuring water fractions.
  • the sensor 114 may also include one or more detectors 206 .
  • the detector 206 may be a photoelectric detector which may detect the scattered and/or reflected light from the patient 204 . Based on the detected light, the detector 206 may generate an electrical signal, e.g., current, at a level corresponding to the detected light. The sensor 114 may direct the electrical signal to the monitor 102 for processing and calculation of physiological parameters.
  • the monitor 102 may be a pulse oximeter, such as those available from Nellcor Puritan Bennett L.L.C.
  • the monitor 102 may include a light drive unit 218 .
  • Light drive unit 218 may be used to control timing of the emitter 202 .
  • An encoder 220 and decoder 222 may be used to calibrate the monitor 102 to the actual wavelengths being used by the emitter 202 .
  • the encoder 220 may be a resistor, for example, whose value corresponds to the actual wavelengths and to coefficients used in algorithms for computing the physiological parameters.
  • the encoder 220 may be a memory device, such as an EPROM, that stores wavelength information and/or the corresponding coefficients.
  • the ROM 216 and the RAM 218 may be used in conjunction, or independently, to store the algorithms used by the processors in computing physiological parameters.
  • the ROM 216 and the RAM 218 may also be used in conjunction, or independently, to store the values detected by the detector 206 for use in the calculation of the aforementioned algorithms.
  • the algorithm stored in the ROM 216 for use by the processor 214 to compute physiological parameters may be a Beer-Lambert and Kohlrausch-Williams-Watts (KWW) product for measuring characteristics of a sample, such as chromophore concentrations in a patient 204 .
  • the probability that an emitted photon passes through a sample and arrives at a detector 206 is
  • ⁇ s may represent the scattering coefficient of the medium and g may represent the anisotropy coefficient of the medium. Furthermore, ⁇ a may be the absorption coefficient.
  • This expression may be derived by assuming that ⁇ is the density function for photon path lengths for a fixed configuration of an emitter 202 , a detector 206 , and a sample site, for example, on a patient 204 .
  • the function for determining the probability of a photon passing through a the zero absorption sample across a distance l, where l is a distance between a to b, (where a to b may be the maximum distance through the medium between the emitter 202 and the detector 206 ), may be found by ⁇ a b ⁇ (x)dx. Therefore, in the absence of absorption,
  • I( ⁇ a , ⁇ s , g) represents the detected intensity at the detector 206 for the given absorption, scattering, and anisotrophy coefficients ⁇ a , ⁇ s , and g.
  • the absorption coefficient does not equal zero.
  • I ⁇ ( ⁇ a , ⁇ s , g ) ⁇ 0 ⁇ ⁇ ⁇ - x ⁇ ⁇ ⁇ a ⁇ f ⁇ ( x ) ⁇ ⁇ ⁇ x .
  • the path length distribution function, ⁇ (x) may be shown to follow a sum-stable distribution.
  • the Laplace transform of a stable distribution with a parameter ⁇ is e ⁇ s ⁇ . Therefore, since ⁇ (x) follows a stable distribution, then I ( ⁇ a , ⁇ s , g) should contain a factor of the form e ⁇ a ⁇ .
  • Modeling ⁇ (x) for the KWW distribution results in
  • I ( ⁇ a , ⁇ s ,g ) C 2 ( ⁇ s ,g ) e ⁇ C 2 ( ⁇ s ,g) ⁇ a ⁇ .
  • C 1 ( ⁇ s , g) may be strictly due to scattering and the geometry of the emitter 202 , the detector 206 , and a sample site, for example, on a patient 204 .
  • ⁇ (x) 0 for all x smaller than the Euclidian distance from the source to the detector, ⁇ (x) should be a shift of a stable distribution.
  • Addition of an extra factor of e ⁇ C 3 ⁇ a to the Laplace transform compensates for the shift, where C 3 may represent the offset distance.
  • the offset distance may be equal to the Euclidean distance between the emitter 202 and the detector 206 . Inclusion of the shift factor results in
  • I ( ⁇ a , ⁇ s ,g ) C 1 ( ⁇ s ,g ) e ⁇ (C 2 ( ⁇ s ,g) ⁇ a ⁇ +C 3 ⁇ a ) .
  • the model can be extended to include the case of collimated, i.e. non-diffused, light where some of the light detected has not been scattered, while other portions of the light has been scattered.
  • the path length distribution function, ⁇ (x) can be described as
  • ⁇ ( x ) g ( x )+ C 4 e ⁇ C 3 ⁇ s ⁇ ( x ⁇ C 3 ).
  • g(x) may be a stable distribution
  • C 4 may represent a coefficient inclusive of the intensity of the emitter 202 and the coupling efficiency of the test geometry
  • ⁇ (x) may be the Dirac delta.
  • the coupling efficiency of the test geometry may take include such factors as the aperature size of the detector 206 as well as the beam diameter.
  • I ( ⁇ a , ⁇ s ,g ) C 1 ( ⁇ s ,g ) e ⁇ (C 2 ( ⁇ s ,g) ⁇ a ⁇ +C 3 ⁇ a ) +C 4 e ⁇ C g ( ⁇ s + ⁇ a ) .
  • This equation represents the general attenuated KWW model for the detected intensity at the detector 206 for the given absorption, scattering, and anisotrophy coefficients ⁇ a , ⁇ s , and g.
  • This general attenuated KWW model may be stored in the ROM 216 for use by the processor 214 in calculating physiological parameters based on the digitized signals from the analog-to-digital converter 212 .
  • the second summand equals zero, for the case when the detector 206 may not be located in the beam path of the emitter 202 .
  • the log of the general attenuated KWW model may be taken, resulting in
  • log I ( ⁇ a , ⁇ s ,g ) ⁇ log C 1 ( ⁇ s ,g )+ C 2 ( ⁇ s ,g ) ⁇ a ⁇ +C 3 ⁇ a .
  • FIG. 3 illustrates a graph 300 of log C 1 ( ⁇ s , g) ⁇ log I( ⁇ a , ⁇ s , g) versus ⁇ a .
  • diffuse reflectance 302 may closely follow the predicted KWW model 304 of diffuse reflectance in sample areas with low absorption rates.
  • diffuse reflectance 302 may closely follow the predicted Beer-Lambert model 306 of diffuse reflectance in sample areas with high absorption rates.
  • ⁇ a ( C 2 ⁇ ( ⁇ s , g ) / C 3 ) 1 1 - ⁇ ,
  • the tendencies of the KWW model 304 and the Beer-Lambert model 306 may be used in the estimation of the concentrations of chemical components of known absorptions.
  • the bulk absorption coefficient may be proportional to U a c, where U a represents the matrix of absorption coefficients of the different components l. If ⁇ s is taken to vary slowly with respect to the wavelength, then the offset and scaling factors will vary slowly with respect to the wavelength, and may be approximated with, for example, B-splines or quadratic polynomials.
  • the general attenuated KWW model becomes
  • F 1 and F 2 may represent matrices whose columns span the spaces containing the approximations of offset and scaling values, and “ ⁇ ” represents the Hadamard, i.e. element by element, product. Furthermore, (U a c) ⁇ may be a Hadamard exponential.
  • the least squares solution may be calculated by the processor 214 using a software program which may be stored on ROM 216 .
  • may be considered a function of ⁇ and ⁇ circumflex over ( ⁇ ) ⁇ . Optimization of ⁇ may be accomplished by an iterative numerical scheme used to compute the gradient of the objective with respect to the vector of free variables.
  • the iterative numerical scheme used may be the Broyden-Fletcher-Goldfarb-Shanno (BFGS) method.
  • the iterative numerical scheme used may be the conjugate gradient method. The gradient will depend on ⁇ 1 , ⁇ 2 , and ⁇ 3 , and in an embodiment, the partial derivatives of ⁇ 1 , ⁇ 2 , and ⁇ 3 may be incorporated into the computation.
  • computational time may be reduced by approximating the gradient by assuming fixed values for ⁇ 1 , ⁇ 2 , and ⁇ 3 .
  • the gradients of ⁇ which can be used to minimize ⁇ with respect to ⁇ and ⁇ circumflex over ( ⁇ ) ⁇ , can be found from
  • ⁇ circumflex over ( ⁇ ) ⁇ may tend towards “1”.
  • ⁇ 1 and ⁇ 2 may be found by
  • a method for using KPLS Regression to formulate a model to be used in conjunction with analyzing spectrographic data may be employed.
  • This method may include the preprocessing of the data with a nonlinear transform to a given space before performing the linear regression into that same space. This may be achieved by use of a kernel function, ⁇ , which may be used to compute the dot product in the given space of two vectors in the data space, without having to perform a transform on that space. This may be accomplished by building a nonlinear model, which may begin with y, some affine function of the concentrations of the components of a given sample.
  • the KPLS may proceed by collecting a number of data samples of optical signals passed through a sample from an emitter 202 to a detector 206 and measured, for example, spectrographically.
  • the processor 214 may then measure an affine function y of the concentrations of the components for each given sample and store it in a vector y.
  • the processor 214 may performing a KPLS regression to find a model of the form
  • This model may then be used to estimate y.
  • we can set a value for ⁇ , or we may determine it from the procedure described above. In either case, an x measurement should take the form of
  • the quadratic equation may be used to yield:
  • ⁇ a - C 2 ⁇ ( ⁇ s , g ) ⁇ C 2 ⁇ ( ⁇ s , g ) 2 + 4 ⁇ ⁇ C 3 ⁇ M ⁇ ( ⁇ a ; ⁇ s , g ) 2 ⁇ ⁇ C 3 ,
  • ⁇ a - C 2 ⁇ ( ⁇ s , g ) 2 ⁇ ⁇ C 3 + ( C 2 ⁇ ( ⁇ s , g ) 2 ⁇ ⁇ C 3 ) 2 + M ⁇ ( ⁇ a ; ⁇ s , g ) C 3 .
  • C 1 ( ⁇ s , g) and C 2 ( ⁇ s , g) may depend on geometry and scattering, while C 3 may depend on the test geometry, only the estimation of ⁇ s , and g is required to be made by the pulse oximeter 100 . This may be accomplished through assumptions as to the tissue sample of the patient 204 which may be stored in the ROM 216 and/or the RAM 218 for use in the calculation of ⁇ a .
  • Another embodiment may be applied when observations are made over time with changes in the absorption of the medium and negligible changes in the scattering properties of the medium.

Abstract

Embodiments disclosed herein may include methods and systems capable of estimating the underlying concentrations of chromophores in a sample. The photon scattering and absorption model may be based on Laplace and stable distributions, which may reveal that measurements in diffuse reflectance may follow a Beer-Lambert and Kohlrausch-Williams-Watts (KWW) product. This Beer-Lambert portion of the product may dominate in high absorption sample areas, while the KWW portion of the product may dominate in low absorption sample areas.

Description

    RELATED APPLICATIONS
  • This application is a divisional of U.S. application Ser. No. 12/412,956, filed Mar. 27, 2009, which claims priority to U.S. Provisional Application No. 61/072,580, filed Mar. 31, 2008, the disclosures of which are hereby incorporated by reference in their entirety.
  • BACKGROUND
  • The present disclosure relates generally to the field of spectroscopy and, more particularly, to a system and method of optimizing the processing spectroscopic data.
  • This section is intended to introduce the reader to various aspects of art that may be related to various aspects that are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of these various aspects. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
  • Spectroscopy may be employed to ascertain the existence and/or concentration of component chemicals in a sample. To perform a spectroscopic analysis on a sample, a source may first send electromagnetic radiation through the sample. The spectrum of electromagnetic radiation which passes through the sample may indicate the absorbance of the sample. Based on the amount and spectrum of the sample absorbance, the presence and/or concentration of distinct chemicals may be detected by employing methods of spectrographic data processing.
  • Typically, the analysis includes modeling the underlying concentrations of chromophores in a sample from spectroscopic observations. The most common method for estimating these chromophores concentrations includes applying a photon scattering and absorption model based solely on the Beer-Lambert Law and utilizing multiple linear regression techniques to approximate the chromophores concentrations. However, the current methods may result in errors on the order of several percent. As such, a method and system for closer approximation of underlying concentrations of chromophores in a sample from spectroscopic observations is needed.
  • SUMMARY
  • Certain aspects commensurate in scope with the originally claimed subject matter are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain embodiments and that these aspects are not intended to limit the scope of the claims. Indeed, the claims may encompass a variety of aspects that may not be set forth below.
  • In accordance with an embodiment, a method of processing spectrographic data may include transmitting an optical signal from an emitter to a sample, receiving the optical signal having passed through the sample at a detector, and analyzing the data associated with the received sample by numerically calculating an approximation of underlying concentrations of chromophores by applying a photon scattering and absorption model based on a mixed Beer-Lambert/Kohlrausch-Williams-Watts Model (KWW) for photon diffusion. In a another embodiment, a method for using Kernel Partial Least Squares (KPLS) Regression to formulate a model to be used in conjunction with analyzing spectrographic data includes collecting a number of data samples of optical signals passed through a sample from an emitter to a detector, measuring an affine function of the concentrations of the components for each given sample, and performing a KPLS regression to find a model for estimating future spectroscopic data.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Certain embodiments may be understood upon reading the following detailed description and upon reference to the drawings in which:
  • FIG. 1 illustrates a perspective view of a pulse oximeter in accordance with an embodiment;
  • FIG. 1A illustrates a perspective view of a sensor in accordance with the pulse oximeter illustrated in FIG. 1;
  • FIG. 2 illustrates a simplified block diagram of a pulse oximeter in FIG. 1, according to an embodiment;
  • FIG. 3 illustrates a graph of diffuse reflectance of a sample area measured by the pulse oximeter in FIG. 1, according to an embodiment.
  • DETAILED DESCRIPTION
  • Various embodiments will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
  • The present disclosure is related to a photon scattering and absorption model which may be applied as an alternative to a strict application of the Beer-Lambert Law for estimation of the underlying concentrations of chromophores in a sample. The photon scattering and absorption model may be based on Laplace and stable distributions which reveal that measurements in diffuse reflectance may follow a Beer-Lambert and Kohlrausch-Williams-Watts (KWW) product. This Beer-Lambert portion of the product may dominate in high absorption sample areas, while the KWW portion of the product may dominate in low absorption sample areas.
  • Turning to FIG. 1, a perspective view of a medical device is illustrated in accordance with an embodiment. The medical device may be a pulse oximeter 100. The pulse oximeter 100 may include a monitor 102. The monitor 102 may be configured to display calculated parameters on a display 104. As illustrated in FIG. 1, the display 104 may be integrated into the monitor 102. However, the monitor 102 may be configured to provide data via a port to a display (not shown) that is not integrated with the monitor 102. The display 104 may be configured to display computed physiological data including, for example, an oxygen saturation percentage, a pulse rate, and/or a plethysmographic waveform 106. As is known in the art, the oxygen saturation percentage may be a functional arterial hemoglobin oxygen saturation measurement in units of percentage SpO2, while the pulse rate may indicate a patient's pulse rate in beats per minute. The monitor 102 may also display information related to alarms, monitor settings, and/or signal quality via indicator lights 108.
  • To facilitate user input, the monitor 102 may include a plurality of control inputs 110. The control inputs 110 may include fixed function keys, programmable function keys, and soft keys. Specifically, the control inputs 110 may correspond to soft key icons in the display 104. Pressing control inputs 110 associated with, or adjacent to, an icon in the display may select a corresponding option. The monitor 102 may also include a casing 118. The casing 118 may aid in the protection of the internal elements of the monitor 102 from damage.
  • The monitor 102 may further include a sensor port 112. The sensor port 112 may allow for connection to an external sensor. FIG. 1A illustrates a sensor 114 that may be used with the monitor 102. The sensor 114 may be communicatively coupled to the monitor 102 via a cable 116 which connects to the sensor port 112. The sensor 114 may be of a disposable or a non-disposable type. Furthermore, the sensor 114 may obtain readings from a patient, which can be used by the monitor to calculate certain physiological characteristics such as the blood-oxygen saturation of hemoglobin in arterial blood, the volume of individual blood pulsations supplying the tissue, and/or the rate of blood pulsations corresponding to each heartbeat of a patient. The sensor 114 and the monitor 102 may combine to form the pulse oximeter 100.
  • Turning to FIG. 2, a simplified block diagram of a medical device is illustrated in accordance with an embodiment. The medical device may be the pulse oximeter 100. The pulse oximeter 100 may include a sensor 114 having one or more emitters 202 configured to transmit electromagnetic radiation, i.e., light, into the tissue of a patient 204. For example, the emitter 202 may include a plurality of LEDs operating at discrete wavelengths, such as in the red and infrared portions of the electromagnetic radiation spectrum. Alternatively, the emitter 202 may be a broad spectrum emitter, or it may include wavelengths for measuring water fractions.
  • The sensor 114 may also include one or more detectors 206. The detector 206 may be a photoelectric detector which may detect the scattered and/or reflected light from the patient 204. Based on the detected light, the detector 206 may generate an electrical signal, e.g., current, at a level corresponding to the detected light. The sensor 114 may direct the electrical signal to the monitor 102 for processing and calculation of physiological parameters.
  • In this embodiment, the monitor 102 may be a pulse oximeter, such as those available from Nellcor Puritan Bennett L.L.C. The monitor 102 may include a light drive unit 218. Light drive unit 218 may be used to control timing of the emitter 202. An encoder 220 and decoder 222 may be used to calibrate the monitor 102 to the actual wavelengths being used by the emitter 202. The encoder 220 may be a resistor, for example, whose value corresponds to the actual wavelengths and to coefficients used in algorithms for computing the physiological parameters. Alternatively, the encoder 220 may be a memory device, such as an EPROM, that stores wavelength information and/or the corresponding coefficients. For example, the encoder 220 may be a memory device such as those found in OxiMax® sensors available from Nellcor Puritan Bennett L.L.C. The encoder 220 may be communicatively coupled to the monitor 102 in order to communicate wavelength information to the decoder 222. The decoder 222 may receive and decode the wavelength information from the encoder 220. Once decoded, the information may be transmitted to the processor 214 for utilization in calculation of the physiological parameters of the patient 108.
  • Further, the monitor 102 may include an amplifier 208 and a filter 124 for amplifying and filtering the electrical signals from the sensor 114 before digitizing the electrical signals in the analog-to-digital converter 212. Once digitized, the signals may be used to calculate the physiological parameters of the patient 204. The monitor 102 may also include one or more processors 214 configured to calculate physiological parameters based on the digitized signals from the analog-to-digital converter 212 and further using algorithms programmed into the monitor 102. The processor 214 may be connected to other component parts of the monitor 102, such as one or more read only memories (ROM) 216, one or more random access memories (RAM) 218, the display 104, and the control inputs 110. The ROM 216 and the RAM 218 may be used in conjunction, or independently, to store the algorithms used by the processors in computing physiological parameters. The ROM 216 and the RAM 218 may also be used in conjunction, or independently, to store the values detected by the detector 206 for use in the calculation of the aforementioned algorithms.
  • In an embodiment, the algorithm stored in the ROM 216 for use by the processor 214 to compute physiological parameters may be a Beer-Lambert and Kohlrausch-Williams-Watts (KWW) product for measuring characteristics of a sample, such as chromophore concentrations in a patient 204. The probability that an emitted photon passes through a sample and arrives at a detector 206 is
  • I ( μ a , μ s , g ) = 0 - x μ a f ( x ) x .
  • In this expression, μs may represent the scattering coefficient of the medium and g may represent the anisotropy coefficient of the medium. Furthermore, μa may be the absorption coefficient. This expression may be derived by assuming that ƒ is the density function for photon path lengths for a fixed configuration of an emitter 202, a detector 206, and a sample site, for example, on a patient 204. Assuming that the medium is non-absorbing at the given wavelength supplied by the emitter 202, i.e μa=0, then the function for determining the probability of a photon passing through a the zero absorption sample across a distance l, where l is a distance between a to b, (where a to b may be the maximum distance through the medium between the emitter 202 and the detector 206), may be found by ∫a bƒ(x)dx. Therefore, in the absence of absorption,

  • I(0,μs ,g)=∫0 ƒ(x)dx
  • where I(μa, μs, g) represents the detected intensity at the detector 206 for the given absorption, scattering, and anisotrophy coefficients μa, μs, and g. However, real world situations may occur where the absorption coefficient does not equal zero.
  • In the case where absorption does not equal zero, according to the Beer-Lambert Law, the probability that a single photon traveling a distance l through a medium with an absorption coefficient of μa will be absorbed is equal to e−tμ a , which follows from the memoryless property and definition of μa. Combined, this yields
  • I ( μ a , μ s , g ) = 0 - x μ a f ( x ) x .
  • Moreover, I(μa, μs, g), may then be the Laplace transform of ƒ i.e. I(μa, μs, g)=L{f}(μa). Thus, the probability that an emitted photon passes through the sample of, for example, a patient 204 is
  • 0 - x μ a f ( x ) x = { f } ( μ a ) .
  • Moreover, the path length distribution function, ƒ(x), may be shown to follow a sum-stable distribution. The Laplace transform of a stable distribution with a parameter α is e−s α . Therefore, since ƒ(x) follows a stable distribution, then I (μa, μs, g) should contain a factor of the form e−μ a β . Modeling ƒ(x) for the KWW distribution results in

  • Ias ,g)=C 2s ,g)e −C 2 s ,g)μ a β .
  • In this equation, C1s, g) may be strictly due to scattering and the geometry of the emitter 202, the detector 206, and a sample site, for example, on a patient 204. However, since ƒ(x)=0 for all x smaller than the Euclidian distance from the source to the detector, ƒ(x) should be a shift of a stable distribution. Addition of an extra factor of e−C 3μa to the Laplace transform compensates for the shift, where C3 may represent the offset distance. The offset distance may be equal to the Euclidean distance between the emitter 202 and the detector 206. Inclusion of the shift factor results in

  • Ias ,g)=C 1s ,g)e −(C 2 s ,g)μ a β +C 3 μ a ).
  • In this embodiment, the model can be extended to include the case of collimated, i.e. non-diffused, light where some of the light detected has not been scattered, while other portions of the light has been scattered. For this embodiment, the path length distribution function, ƒ(x), can be described as

  • ƒ(x)=g(x)+C 4 e −C 3 μ s δ(x−C 3).
  • Here, g(x) may be a stable distribution, C4 may represent a coefficient inclusive of the intensity of the emitter 202 and the coupling efficiency of the test geometry, and δ(x) may be the Dirac delta. The coupling efficiency of the test geometry may take include such factors as the aperature size of the detector 206 as well as the beam diameter. By the linearity of the Laplace transform, this yields

  • Ias ,g)=C 1s ,g)e −(C 2 s ,g)μ a β +C 3 μ a ) +C 4 e −C g s a ).
  • This equation represents the general attenuated KWW model for the detected intensity at the detector 206 for the given absorption, scattering, and anisotrophy coefficients μa, μs, and g. This general attenuated KWW model may be stored in the ROM 216 for use by the processor 214 in calculating physiological parameters based on the digitized signals from the analog-to-digital converter 212.
  • In an embodiment (in the case of diffuse reflectance), the second summand equals zero, for the case when the detector 206 may not be located in the beam path of the emitter 202. The log of the general attenuated KWW model may be taken, resulting in

  • log Ias ,g)=−log C 1s ,g)+C 2s ,ga β +C 3μa.
  • As log C1s, g) can be estimated, then log C1s, g)−log I(μa, μs, g) versus μa may be plotted graphically. FIG. 3 illustrates a graph 300 of log C1s, g)−log I(μa, μs, g) versus μa. As seen from the graph 300, diffuse reflectance 302 may closely follow the predicted KWW model 304 of diffuse reflectance in sample areas with low absorption rates. Conversely, diffuse reflectance 302 may closely follow the predicted Beer-Lambert model 306 of diffuse reflectance in sample areas with high absorption rates. The crossover point 308 where the two terms trade dominance occurs at
  • μ a = ( C 2 ( μ s , g ) / C 3 ) 1 1 - β ,
  • while far from the crossover point on each end of the diffuse reflectance 302 may be well approximated by the summands C2s, g)μa β for the predicted KWW model 304, and C3μa for the Beer-Lambert model 306.
  • The tendencies of the KWW model 304 and the Beer-Lambert model 306 may be used in the estimation of the concentrations of chemical components of known absorptions. Thus, when a sample consists of l chemical components of varying concentrations c may be subject to light of different wavelengths, and the intensity at the detector 206 has been recorded, then the bulk absorption coefficient may be proportional to Uac, where Ua represents the matrix of absorption coefficients of the different components l. If μs is taken to vary slowly with respect to the wavelength, then the offset and scaling factors will vary slowly with respect to the wavelength, and may be approximated with, for example, B-splines or quadratic polynomials. Thus, the general attenuated KWW model becomes

  • m=F 1 c 1+(F 2 c 2)⊙(U a c)β +C 3(U a c),
  • where m represents the vector of the negative log intensity values, F1 and F2 may represent matrices whose columns span the spaces containing the approximations of offset and scaling values, and “⊙” represents the Hadamard, i.e. element by element, product. Furthermore, (Uac)β may be a Hadamard exponential.
  • For given estimates of c and p, the optimal values for c1 and c2 may be easily computed. Thus, determining the values used as estimations for c and β remains. Let ĉ, {circumflex over (β)}, ĉ1, ĉ2, Ĉ3 represent estimates of the unknown quantities. The residual may then be defined as

  • ε=m−F 1 ĉ 1−(F 2 ĉ 2)⊙(U a ĉ){circumflex over (β)} −Ĉ 3(U a ĉ),
  • while the square error of the approximation may be

  • Ø(ĉ 1 2 3 ,ĉ,{circumflex over (β)})=εTε.
  • Therefore, to find the ĉ1ĉ2 and Ĉ3, which minimize ⊙ for fixed ĉ, {circumflex over (β)}, we may estimate the vector of the negative log intensity values as
  • m F 1 c ^ 1 + diag ( ( U a c ^ ) β ^ ) F 2 c ^ 2 + C ^ 3 U a c ^ = [ F 1 diag ( ( U a c ^ ) β ^ ) F 2 U a c ^ ] [ c ^ 1 c ^ 2 C ^ 3 ] = A [ c ^ 1 c ^ 2 C ^ 3 ] ,
  • where diag (ν) represents the square diagonal matrix with diagonal ν and A=(ĉ,{circumflex over (β)})=

  • A=(ĉ,{circumflex over (β)})=[F 1diag((U a ĉ){circumflex over (β)}) F 2 U a ĉ].
  • The least squares optimal ĉ1ĉ2 and Ĉ3 can then be described by the normal equation form
  • [ c ^ 1 c ^ 2 C ^ 3 ] = ( A T A ) - 1 A T m .
  • In an embodiment, the least squares solution may be calculated by the processor 214 using a software program which may be stored on ROM 216.
  • Ø may be considered a function of ĉ and {circumflex over (β)}. Optimization of Ø may be accomplished by an iterative numerical scheme used to compute the gradient of the objective with respect to the vector of free variables. In an embodiment, the iterative numerical scheme used may be the Broyden-Fletcher-Goldfarb-Shanno (BFGS) method. In another embodiment, the iterative numerical scheme used may be the conjugate gradient method. The gradient will depend on ĉ1, ĉ2, and Ĉ3, and in an embodiment, the partial derivatives of ĉ1, ĉ2, and Ĉ3 may be incorporated into the computation. In another embodiment, computational time may be reduced by approximating the gradient by assuming fixed values for ĉ1, ĉ2, and Ĉ3. Under this assumption, the gradients of Ø, which can be used to minimize Ø with respect to ĉ and {circumflex over (β)}, can be found from
  • ( c ^ 1 , c ^ 2 , C ^ 3 , c ^ , β ^ ) β ^ = - 2 ( ε F 2 c ^ 2 ( U a c ^ ) β ^ ) T log ( U a c ^ ) and c ^ ( c ^ 1 , c ^ 2 , C ^ 3 , c ^ , β ^ ) = - 2 U a T ( β ^ ε F 2 c ^ 2 ( U a c ^ ) β ^ - 1 + C ^ 3 ε ) .
  • When the processor 214 determines that the μa values fall into the dominant region of either the predicted KWW model 304 or the predicted Beer-Lambert model 306, the final summand of

  • m=F 1 C 1+(F 2 C 2)⊙(U a c){circumflex over (β)} +C 3(U a C)
  • may be eliminated. For example, when the Beer-Lambert model 306 dominates, then {circumflex over (β)} may tend towards “1”. Assuming that the space spanned by the columns of F2 represent a constant, which occurs if F2 spans a B-spline or a polynomial space (in μa). In this form, ĉ1 and ĉ2 may be found by
  • [ c ^ 1 c ^ 2 ] = ( B T B ) - 1 B T m , where B = B ( c ^ , β ^ ) = [ F 1 diag ( ( U a c ^ ) β ^ ) F 2 ] .
  • This results in the gradients of Ø being solved by
  • ( c ^ 1 , c ^ 2 , c ^ , β ^ ) β ^ = - 2 ( ε F 2 c ^ 2 ( U a c ^ ) β ^ ) T log ( U a c ^ ) and c ^ ( c ^ 1 , c ^ 2 , c ^ , β ^ ) = 2 β ^ U a T ( ε F 2 c ^ 2 ( U a c ^ ) β ^ - 1 ) .
  • In another embodiment, a method for using KPLS Regression to formulate a model to be used in conjunction with analyzing spectrographic data may be employed. This method may include the preprocessing of the data with a nonlinear transform to a given space before performing the linear regression into that same space. This may be achieved by use of a kernel function, κ, which may be used to compute the dot product in the given space of two vectors in the data space, without having to perform a transform on that space. This may be accomplished by building a nonlinear model, which may begin with y, some affine function of the concentrations of the components of a given sample. The KPLS may proceed by collecting a number of data samples of optical signals passed through a sample from an emitter 202 to a detector 206 and measured, for example, spectrographically. The processor 214 may then measure an affine function y of the concentrations of the components for each given sample and store it in a vector y. The processor 214 may performing a KPLS regression to find a model of the form
  • y i y o + j a j k ( X j , : , X i , : ) .
  • This model may then be used to estimate y.
  • To determine κ, we can set a value for β, or we may determine it from the procedure described above. In either case, an x measurement should take the form of

  • x=h+ma T c)β.
  • Since a lower bound on h can be determined for a given sensor 114, its value may be set as small relative to the second summand. From
  • μ a T c = [ ( x - h ) / m ] 1 β ,
  • using a Taylor expansion, we may determine
  • μ a T c 1 m 1 β [ x 1 β - 1 β x 1 β - 1 h ] .
  • This suggests the use of
  • κ ( x , y ) = ( x T y ) 1 β or κ ( x , y ) = ( x T y ) 1 β + ( x T y ) 1 β - 1
  • as kernels.
  • A specific embodiment may include β=½, where μs, and g are fixed. In this case, the function

  • (C 2s ,ga β +C 3μa)
  • may be an injunctive function, i.e. one-to-one, with respect to μa. Thus, the function has an inverse. As such, an optical observation may be transformed to a quantity proportional to μa, thus linearizing the signal. Therefore, once C1sg) is estimated, the quantity

  • Mas ,g)=df log C 1s ,g)−log Ias ,g)=C 2s ga β +C 3μa
  • may be computed from the optical observations of I(μa, μs, g). Moreover, since β=½, the observations are explicitly invertible to
  • M ( μ a ; μ s , g ) = C 2 ( μ s , g ) μ a 1 2 + C 3 μ a 0 = C 3 ( μ a ) 2 + C 2 ( μ s , g ) μ a - M ( μ a ; μ s , g ) .
  • The quadratic equation may be used to yield:
  • μ a = - C 2 ( μ s , g ) ± C 2 ( μ s , g ) 2 + 4 C 3 M ( μ a ; μ s , g ) 2 C 3 ,
  • the negative root of which may be ignored to generate
  • μ a = - C 2 ( μ s , g ) 2 C 3 + ( C 2 ( μ s , g ) 2 C 3 ) 2 + M ( μ a ; μ s , g ) C 3 .
  • Furthermore, by letting κ=C2s, g)/2C3, the equation becomes:
  • μ a = ( - κ + κ 2 + M ( μ a ; μ s , g ) C 3 ) 2 = 2 κ 2 + M ( μ a ; μ s , g ) C 3 - 2 κ κ 2 + M ( μ a ; μ s , g ) C 3 .
  • Accordingly, because C1s, g) and C2s, g) may depend on geometry and scattering, while C3 may depend on the test geometry, only the estimation of μs, and g is required to be made by the pulse oximeter 100. This may be accomplished through assumptions as to the tissue sample of the patient 204 which may be stored in the ROM 216 and/or the RAM 218 for use in the calculation of μa.
  • Another embodiment may be applied when observations are made over time with changes in the absorption of the medium and negligible changes in the scattering properties of the medium. For
  • - log I ( μ a , μ s , g , t ) t = C 2 ( μ s , g ) βμ a β - 1 μ a t + C 3 μ a t ,
  • it may be shown that
  • - log I ( μ a , μ s , g , t ) t
  • may be large when μa is small, which contrasts with the expected values from the Beer-Lambert Law that
  • - log I ( μ a , μ s , g , t ) t = C 3 μ a t
  • holds steady for all values of μa. When observations are made at n wavelengths over a sample containing l chemical components of varying concentrations c(t), with Ua as the (n×l) matrix of absorption coefficients of the different components at the different wavelengths, then the vector of μa at the n wavelengths is Uac(t). If m is the n-vector of observed
  • - log I ( μ a , μ s , g , t ) t
  • values at a fixed time at the given wavelength,
    then
  • m = [ C 2 ( μ s , g ) β ( U a c ( t ) ) β - 1 + C 3 I ] U a c ( t ) t .
  • As such, when U, c(t) is estimated, then the left Hadamard multiplicand may be estimated, resulting in
  • g C 2 ( μ s , g ) β ( U a c ( t ) ) β - 1 + C 3 I and m ( diag ( g ) U a ) c ( t ) t ,
  • for which
  • c ( t ) t
  • be estimated, for example, using the least squares method.
  • Specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the claims are not intended to be limited to the particular forms disclosed. Rather the claims are to cover all modifications, equivalents, and alternatives falling within their spirit and scope.

Claims (22)

1. A method for determining the concentration of a component in a tissue sample of a patient, comprising:
collecting a plurality of physiologic signals from a tissue sample of a patient;
measuring, for each physiologic signal, a concentration of a component of the tissue sample; and
performing a Kernel Partial Least Squares regression on the concentration of the component.
2. The method of claim 1, comprising determining a model for the tissue sample based at least in part upon the Kernel Partial Least Squares regression.
3. The method of claim 2, comprising applying the model to a second tissue sample.
4. The method of claim 2, wherein the model comprises a nonlinear model.
5. The method of claim 1, comprising calculating a kernel function for use with the Kernel Partial Least Squares regression.
6. The method of claim 1, wherein collecting the plurality of physiologic signals comprises:
emitting light into the tissue of the patient;
detecting scattered or reflected light from the tissue; and
generating the plurality of physiologic signals corresponding to the detected light.
7. The method of claim 1, wherein the concentration comprises a concentration of chromophores in the tissue sample.
8. A system for determining the concentration of a component in a patient's tissue, comprising:
a sensor configured to obtain a plurality of physiologic signals from a patient;
a monitor configured to receive from the sensor the plurality of physiologic signals; and
a processor configured to:
measure, for each physiologic signal, a concentration of a component of the tissue; and
perform a Kernel Partial Least Squares regression on the concentration of the component.
9. The system of claim 8, wherein the sensor is configured to emit light into a tissue of the patient and to detect scattered or reflected light from the tissue.
10. The system of claim 9, wherein the plurality of physiologic signals corresponds to the detected light.
11. The system of claim 8, wherein the monitor comprises a pulse oximeter.
12. The system of claim 8, wherein the processor is configured to determine a model for the tissue based at least in part upon the Kernel Partial Least Squares regression.
13. The system of claim 12, wherein the processor is configured to apply the model to a second tissue sample.
14. The system of claim 12, wherein the model comprises a nonlinear model.
15. The system of claim 8, wherein the processor is configured to calculate a kernel function for use with the Kernel Partial Least Squares regression.
16. The system of claim 8, further comprising a memory device coupled to the processor and storing an assumption regarding the tissue, for use in the Kernel Partial Least Squares regression.
17. The system of claim 8, wherein the concentration comprises a concentration of chromophores in the tissue.
18. A medical device for determining the concentration of a component in a tissue sample, comprising:
a processor configured to:
collect a plurality of physiologic signals from a tissue sample of a patient;
measure, for each physiologic signal, a concentration of a component of the tissue sample; and
perform a Kernel Partial Least Squares regression on the concentration of the component.
19. The medical device of claim 18, wherein the processor is configured to determine a model for the tissue sample based at least in part upon the Kernel Partial Least Squares regression.
20. The medical device of claim 19, wherein the processor is configured to apply the model to a second tissue sample.
21. The medical device of claim 18, wherein the medical device comprises a pulse oximeter.
22. A method for determining a chromophore concentration in a tissue area of a patient, comprising:
emitting electromagnetic radiation into a tissue area of a patient;
detecting radiation scattered and/or reflected by the tissue area;
generating a physiologic signal corresponding to the detected radiation;
collecting a plurality of data samples from the signal;
measuring, for each data sample, an affine function of a chromophore concentration; and
performing a Kernel Partial Least Squares regression to obtain a model for the tissue area.
US13/625,707 2008-03-31 2012-09-24 Detecting chemical components from spectroscopic observations Abandoned US20130024129A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/625,707 US20130024129A1 (en) 2008-03-31 2012-09-24 Detecting chemical components from spectroscopic observations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7258008P 2008-03-31 2008-03-31
US12/412,956 US8292809B2 (en) 2008-03-31 2009-03-27 Detecting chemical components from spectroscopic observations
US13/625,707 US20130024129A1 (en) 2008-03-31 2012-09-24 Detecting chemical components from spectroscopic observations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/412,956 Division US8292809B2 (en) 2008-03-31 2009-03-27 Detecting chemical components from spectroscopic observations

Publications (1)

Publication Number Publication Date
US20130024129A1 true US20130024129A1 (en) 2013-01-24

Family

ID=41118224

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/412,956 Active 2031-08-15 US8292809B2 (en) 2008-03-31 2009-03-27 Detecting chemical components from spectroscopic observations
US13/625,707 Abandoned US20130024129A1 (en) 2008-03-31 2012-09-24 Detecting chemical components from spectroscopic observations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/412,956 Active 2031-08-15 US8292809B2 (en) 2008-03-31 2009-03-27 Detecting chemical components from spectroscopic observations

Country Status (1)

Country Link
US (2) US8292809B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150103389A1 (en) * 2012-05-25 2015-04-16 View, Inc. Portable power supplies and portable controllers for smart windows

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102178536B (en) * 2011-03-29 2013-04-03 苏州易寻传感网络科技有限公司 Method and system for measuring oxygen saturation and heart rate
CN106096547B (en) * 2016-06-11 2019-02-19 北京工业大学 A kind of low-resolution face image feature super resolution ratio reconstruction method towards identification
US10996173B2 (en) * 2017-08-15 2021-05-04 Seti Institute Non-linear methods for quantitative elemental analysis and mineral classification using laser-induced breakdown spectroscopy (LIBS)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5630413A (en) * 1992-07-06 1997-05-20 Sandia Corporation Reliable noninvasive measurement of blood gases
US20060220881A1 (en) * 2005-03-01 2006-10-05 Ammar Al-Ali Noninvasive multi-parameter patient monitor

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3638640A (en) 1967-11-01 1972-02-01 Robert F Shaw Oximeter and method for in vivo determination of oxygen saturation in blood using three or more different wavelengths
US4938218A (en) 1983-08-30 1990-07-03 Nellcor Incorporated Perinatal pulse oximetry sensor
US4714341A (en) 1984-02-23 1987-12-22 Minolta Camera Kabushiki Kaisha Multi-wavelength oximeter having a means for disregarding a poor signal
US4911167A (en) 1985-06-07 1990-03-27 Nellcor Incorporated Method and apparatus for detecting optical pulses
US4936679A (en) 1985-11-12 1990-06-26 Becton, Dickinson And Company Optical fiber transducer driving and measuring circuit and method for using same
US4913150A (en) 1986-08-18 1990-04-03 Physio-Control Corporation Method and apparatus for the automatic calibration of signals employed in oximetry
US4773422A (en) 1987-04-30 1988-09-27 Nonin Medical, Inc. Single channel pulse oximeter
SE458153B (en) 1987-07-16 1989-02-27 Polymetric Ab OPTICAL ANGLE METHODON
US4805623A (en) 1987-09-04 1989-02-21 Vander Corporation Spectrophotometric method for quantitatively determining the concentration of a dilute component in a light- or other radiation-scattering environment
US4807631A (en) 1987-10-09 1989-02-28 Critikon, Inc. Pulse oximetry system
DE3877894T2 (en) 1987-11-02 1993-06-24 Sumitomo Electric Industries ORGANIC LIGHT MEASURING PROBE.
JPH0288041A (en) 1988-09-24 1990-03-28 Misawahoomu Sogo Kenkyusho:Kk Finger tip pulse wave sensor
US5122974A (en) 1989-02-06 1992-06-16 Nim, Inc. Phase modulated spectrophotometry
US5873821A (en) 1992-05-18 1999-02-23 Non-Invasive Technology, Inc. Lateralization spectrophotometer
US5564417A (en) 1991-01-24 1996-10-15 Non-Invasive Technology, Inc. Pathlength corrected oximeter and the like
US4972331A (en) 1989-02-06 1990-11-20 Nim, Inc. Phase modulated spectrophotometry
CA1331483C (en) 1988-11-02 1994-08-16 Britton Chance User-wearable hemoglobinometer for measuring the metabolic condition of a subject
EP0374668A3 (en) 1988-12-16 1992-02-05 A.W. Faber - Castell GmbH & Co. Fluorescent marking fluid
US5119815A (en) 1988-12-21 1992-06-09 Nim, Incorporated Apparatus for determining the concentration of a tissue pigment of known absorbance, in vivo, using the decay characteristics of scintered electromagnetic radiation
US5553614A (en) 1988-12-21 1996-09-10 Non-Invasive Technology, Inc. Examination of biological tissue using frequency domain spectroscopy
US5028787A (en) 1989-01-19 1991-07-02 Futrex, Inc. Non-invasive measurement of blood glucose
US6708048B1 (en) 1989-02-06 2004-03-16 Non-Invasive Technology, Inc. Phase modulation spectrophotometric apparatus
US6183414B1 (en) 1999-04-26 2001-02-06 Michael S. Wysor Technique for restoring plasticity to tissues of a male or female organ
US5483646A (en) 1989-09-29 1996-01-09 Kabushiki Kaisha Toshiba Memory access control method and system for realizing the same
US5190038A (en) 1989-11-01 1993-03-02 Novametrix Medical Systems, Inc. Pulse oximeter with improved accuracy and response time
DE3938759A1 (en) 1989-11-23 1991-05-29 Philips Patentverwaltung NON-INVASIVE OXIMETER ARRANGEMENT
US6266546B1 (en) 1990-10-06 2001-07-24 In-Line Diagnostics Corporation System for noninvasive hematocrit monitoring
US6246894B1 (en) 1993-02-01 2001-06-12 In-Line Diagnostics Corporation System and method for measuring blood urea nitrogen, blood osmolarity, plasma free hemoglobin and tissue water content
US6681128B2 (en) 1990-10-06 2004-01-20 Hema Metrics, Inc. System for noninvasive hematocrit monitoring
US5372136A (en) 1990-10-06 1994-12-13 Noninvasive Medical Technology Corporation System and method for noninvasive hematocrit monitoring
EP1357481A3 (en) 1991-03-07 2005-04-27 Masimo Corporation Signal processing apparatus and method
US5995855A (en) 1998-02-11 1999-11-30 Masimo Corporation Pulse oximetry sensor adapter
US6580086B1 (en) 1999-08-26 2003-06-17 Masimo Corporation Shielded optical probe and method
US5638818A (en) 1991-03-21 1997-06-17 Masimo Corporation Low noise optical probe
DE4138702A1 (en) 1991-03-22 1992-09-24 Madaus Medizin Elektronik METHOD AND DEVICE FOR THE DIAGNOSIS AND QUANTITATIVE ANALYSIS OF APNOE AND FOR THE SIMULTANEOUS DETERMINATION OF OTHER DISEASES
US6549795B1 (en) 1991-05-16 2003-04-15 Non-Invasive Technology, Inc. Spectrophotometer for tissue examination
US5246003A (en) 1991-08-28 1993-09-21 Nellcor Incorporated Disposable pulse oximeter sensor
US6987994B1 (en) 1991-09-03 2006-01-17 Datex-Ohmeda, Inc. Pulse oximetry SpO2 determination
US5247931A (en) 1991-09-16 1993-09-28 Mine Safety Appliances Company Diagnostic sensor clasp utilizing a slot, pivot and spring hinge mechanism
DE59209492D1 (en) 1992-01-25 1998-10-15 Alsthom Cge Alcatel Procedures to facilitate the operation of end devices in telecommunications systems
US5385143A (en) 1992-02-06 1995-01-31 Nihon Kohden Corporation Apparatus for measuring predetermined data of living tissue
US5297548A (en) 1992-02-07 1994-03-29 Ohmeda Inc. Arterial blood monitoring probe
US5263244A (en) 1992-04-17 1993-11-23 Gould Inc. Method of making a flexible printed circuit sensor assembly for detecting optical pulses
JP3170866B2 (en) 1992-04-24 2001-05-28 株式会社ノーリツ 1 can 2 circuit type instant heating type heat exchanger
DE69211986T2 (en) 1992-05-15 1996-10-31 Hewlett Packard Gmbh Medical sensor
US6785568B2 (en) 1992-05-18 2004-08-31 Non-Invasive Technology Inc. Transcranial examination of the brain
US5680857A (en) 1992-08-28 1997-10-28 Spacelabs Medical, Inc. Alignment guide system for transmissive pulse oximetry sensors
EP0684575A4 (en) 1993-12-14 1997-05-14 Mochida Pharm Co Ltd Medical measuring apparatus.
US5645059A (en) 1993-12-17 1997-07-08 Nellcor Incorporated Medical sensor with modulated encoding scheme
JP3238813B2 (en) 1993-12-20 2001-12-17 テルモ株式会社 Pulse oximeter
JP3464697B2 (en) 1993-12-21 2003-11-10 興和株式会社 Oxygen saturation meter
US5995859A (en) 1994-02-14 1999-11-30 Nihon Kohden Corporation Method and apparatus for accurately measuring the saturated oxygen in arterial blood by substantially eliminating noise from the measurement signal
DE4423597C1 (en) 1994-07-06 1995-08-10 Hewlett Packard Gmbh Pulsoximetric ear sensor
JP2780935B2 (en) 1994-09-22 1998-07-30 浜松ホトニクス株式会社 Method and apparatus for measuring concentration of absorption component of scattering absorber
US5692503A (en) 1995-03-10 1997-12-02 Kuenstner; J. Todd Method for noninvasive (in-vivo) total hemoglobin, oxyhemogolobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin concentration determination
US7035697B1 (en) 1995-05-30 2006-04-25 Roy-G-Biv Corporation Access control systems and methods for motion control
US5758644A (en) 1995-06-07 1998-06-02 Masimo Corporation Manual and automatic probe calibration
US5645060A (en) 1995-06-14 1997-07-08 Nellcor Puritan Bennett Incorporated Method and apparatus for removing artifact and noise from pulse oximetry
US5853364A (en) 1995-08-07 1998-12-29 Nellcor Puritan Bennett, Inc. Method and apparatus for estimating physiological parameters using model-based adaptive filtering
US5995856A (en) 1995-11-22 1999-11-30 Nellcor, Incorporated Non-contact optical monitoring of physiological parameters
SE9600322L (en) 1996-01-30 1997-07-31 Hoek Instr Ab Sensor for pulse oximetry with fiber optic signal transmission
US6181959B1 (en) 1996-04-01 2001-01-30 Kontron Instruments Ag Detection of parasitic signals during pulsoxymetric measurement
JP3662376B2 (en) 1996-05-10 2005-06-22 浜松ホトニクス株式会社 Internal characteristic distribution measuring method and apparatus
US5842981A (en) 1996-07-17 1998-12-01 Criticare Systems, Inc. Direct to digital oximeter
US6163715A (en) 1996-07-17 2000-12-19 Criticare Systems, Inc. Direct to digital oximeter and method for calculating oxygenation levels
US6544193B2 (en) 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US5830139A (en) 1996-09-04 1998-11-03 Abreu; Marcio M. Tonometer system for measuring intraocular pressure by applanation and/or indentation
US6120460A (en) 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US5871442A (en) 1996-09-10 1999-02-16 International Diagnostics Technologies, Inc. Photonic molecular probe
CN1203805C (en) 1996-09-10 2005-06-01 精工爱普生株式会社 Organism state measuring device and relaxation instructing device
US5830136A (en) 1996-10-31 1998-11-03 Nellcor Puritan Bennett Incorporated Gel pad optical sensor
US6487439B1 (en) 1997-03-17 2002-11-26 Victor N. Skladnev Glove-mounted hybrid probe for tissue type recognition
AUPO676397A0 (en) 1997-05-13 1997-06-05 Dunlop, Colin Method and apparatus for monitoring haemodynamic function
CN1309341C (en) 1997-06-17 2007-04-11 里普朗尼克股份有限公司 Fetal oximetry system and sensor
AU7934498A (en) 1997-06-27 1999-01-19 Toa Medical Electronics Co., Ltd. Living body inspecting apparatus and noninvasive blood analyzer using the same
FI973454A (en) 1997-08-22 1999-02-23 Instrumentarium Oy A resilient device in a measuring sensor for observing the properties of living tissue
DE69700384T2 (en) 1997-12-22 1999-11-25 Hewlett Packard Co Telemetry system, in particular for medical purposes
JP3567319B2 (en) 1997-12-26 2004-09-22 日本光電工業株式会社 Probe for pulse oximeter
JP2002501803A (en) 1998-02-05 2002-01-22 イン−ラインダイアグノスティックスコーポレイション Non-invasive blood component monitoring method and apparatus
US5924980A (en) 1998-03-11 1999-07-20 Siemens Corporate Research, Inc. Method and apparatus for adaptively reducing the level of noise in an acquired signal
JP3576851B2 (en) 1998-03-23 2004-10-13 キヤノン株式会社 Liquid crystal display, video camera
JP4018799B2 (en) 1998-04-02 2007-12-05 浜松ホトニクス株式会社 Method and apparatus for measuring concentration of absorption component of scattering medium
US6662030B2 (en) 1998-05-18 2003-12-09 Abbott Laboratories Non-invasive sensor having controllable temperature feature
JP3887486B2 (en) 1998-05-26 2007-02-28 浜松ホトニクス株式会社 Method and apparatus for measuring internal characteristic distribution of scattering medium
IL124787A0 (en) 1998-06-07 1999-01-26 Itamar Medical C M 1997 Ltd Pressure applicator devices particularly useful for non-invasive detection of medical conditions
US5920263A (en) 1998-06-11 1999-07-06 Ohmeda, Inc. De-escalation of alarm priorities in medical devices
US6842635B1 (en) 1998-08-13 2005-01-11 Edwards Lifesciences Llc Optical device
US6671526B1 (en) 1998-07-17 2003-12-30 Nihon Kohden Corporation Probe and apparatus for determining concentration of light-absorbing materials in living tissue
JP2000083933A (en) 1998-07-17 2000-03-28 Nippon Koden Corp Instrument for measuring concentration of light absorptive material in vital tissue
US6949081B1 (en) 1998-08-26 2005-09-27 Non-Invasive Technology, Inc. Sensing and interactive drug delivery
US6064898A (en) 1998-09-21 2000-05-16 Essential Medical Devices Non-invasive blood component analyzer
US6684090B2 (en) 1999-01-07 2004-01-27 Masimo Corporation Pulse oximetry data confidence indicator
US6606511B1 (en) 1999-01-07 2003-08-12 Masimo Corporation Pulse oximetry pulse indicator
US6658276B2 (en) 1999-01-25 2003-12-02 Masimo Corporation Pulse oximeter user interface
US6438399B1 (en) 1999-02-16 2002-08-20 The Children's Hospital Of Philadelphia Multi-wavelength frequency domain near-infrared cerebral oximeter
US6360114B1 (en) 1999-03-25 2002-03-19 Masimo Corporation Pulse oximeter probe-off detector
US6402986B1 (en) 1999-07-16 2002-06-11 The Trustees Of Boston University Compositions and methods for luminescence lifetime comparison
US6675029B2 (en) 1999-07-22 2004-01-06 Sensys Medical, Inc. Apparatus and method for quantification of tissue hydration using diffuse reflectance spectroscopy
US6512937B2 (en) 1999-07-22 2003-01-28 Sensys Medical, Inc. Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction
US7904139B2 (en) 1999-08-26 2011-03-08 Non-Invasive Technology Inc. Optical examination of biological tissue using non-contact irradiation and detection
US6618042B1 (en) 1999-10-28 2003-09-09 Gateway, Inc. Display brightness control method and apparatus for conserving battery power
JP2001149349A (en) 1999-11-26 2001-06-05 Nippon Koden Corp Sensor for living body
US6622095B2 (en) 1999-11-30 2003-09-16 Nihon Kohden Corporation Apparatus for determining concentrations of hemoglobins
US6415236B2 (en) 1999-11-30 2002-07-02 Nihon Kohden Corporation Apparatus for determining concentrations of hemoglobins
AU1678800A (en) 1999-12-22 2001-07-03 Orsense Ltd. A method of optical measurements for determining various parameters of the patient's blood
US6419671B1 (en) 1999-12-23 2002-07-16 Visx, Incorporated Optical feedback system for vision correction
US6594513B1 (en) 2000-01-12 2003-07-15 Paul D. Jobsis Method and apparatus for determining oxygen saturation of blood in body organs
IL135077A0 (en) 2000-03-15 2001-05-20 Orsense Ltd A probe for use in non-invasive measurements of blood related parameters
CA2405825C (en) 2000-04-17 2010-11-09 Nellcor Puritan Bennett Incorporated Pulse oximeter sensor with piece-wise function
US6889153B2 (en) 2001-08-09 2005-05-03 Thomas Dietiker System and method for a self-calibrating non-invasive sensor
IL138683A0 (en) 2000-09-25 2001-10-31 Vital Medical Ltd Apparatus and method for monitoring tissue vitality parameters
IL138884A (en) 2000-10-05 2006-07-05 Conmed Corp Pulse oximeter and a method of its operation
US6466809B1 (en) 2000-11-02 2002-10-15 Datex-Ohmeda, Inc. Oximeter sensor having laminated housing with flat patient interface surface
US6501974B2 (en) 2001-01-22 2002-12-31 Datex-Ohmeda, Inc. Compensation of human variability in pulse oximetry
US6606509B2 (en) 2001-03-16 2003-08-12 Nellcor Puritan Bennett Incorporated Method and apparatus for improving the accuracy of noninvasive hematocrit measurements
US7239902B2 (en) 2001-03-16 2007-07-03 Nellor Puritan Bennett Incorporated Device and method for monitoring body fluid and electrolyte disorders
US6591122B2 (en) 2001-03-16 2003-07-08 Nellcor Puritan Bennett Incorporated Device and method for monitoring body fluid and electrolyte disorders
US6898451B2 (en) 2001-03-21 2005-05-24 Minformed, L.L.C. Non-invasive blood analyte measuring system and method utilizing optical absorption
US20020156354A1 (en) 2001-04-20 2002-10-24 Larson Eric Russell Pulse oximetry sensor with improved spring
JP4464128B2 (en) 2001-06-20 2010-05-19 パーデュー リサーチ ファウンデーション Site irradiation pressure zone for in vitro optical measurement of blood indicators
SG126677A1 (en) 2001-06-26 2006-11-29 Meng Ting Choon Method and device for measuring blood sugar level
US6697658B2 (en) 2001-07-02 2004-02-24 Masimo Corporation Low power pulse oximeter
DE10139379A1 (en) 2001-08-10 2003-03-06 Siemens Ag Inductive motion sensor has sensor coils beside permanent magnet field generator
US6654621B2 (en) 2001-08-29 2003-11-25 Bci, Inc. Finger oximeter with finger grip suspension system
US6668183B2 (en) 2001-09-11 2003-12-23 Datex-Ohmeda, Inc. Diode detection circuit
IL145445A (en) 2001-09-13 2006-12-31 Conmed Corp Signal processing method and device for signal-to-noise improvement
US7162306B2 (en) 2001-11-19 2007-01-09 Medtronic Physio - Control Corp. Internal medical device communication bus
JP3709836B2 (en) 2001-11-20 2005-10-26 コニカミノルタセンシング株式会社 Blood component measuring device
JP2003194714A (en) 2001-12-28 2003-07-09 Omega Wave Kk Measuring apparatus for blood amount in living-body tissue
JP2003210438A (en) 2002-01-22 2003-07-29 Tyco Healthcare Japan Inc Adapter for oximeter
US6822564B2 (en) 2002-01-24 2004-11-23 Masimo Corporation Parallel measurement alarm processor
ATE369788T1 (en) 2002-01-31 2007-09-15 Univ Loughborough VENOUS PULSE OXYMETERY
EP1475037B1 (en) 2002-02-14 2012-09-12 Toshinori Kato Apparatus for evaluating biological function
US6961598B2 (en) 2002-02-22 2005-11-01 Masimo Corporation Pulse and active pulse spectraphotometry
WO2003073924A1 (en) 2002-03-01 2003-09-12 Terry Beaumont Ear canal sensing device
US6863652B2 (en) 2002-03-13 2005-03-08 Draeger Medical Systems, Inc. Power conserving adaptive control system for generating signal in portable medical devices
DE10213692B4 (en) 2002-03-27 2013-05-23 Weinmann Diagnostics Gmbh & Co. Kg Method for controlling a device and device for measuring ingredients in the blood
US6690958B1 (en) 2002-05-07 2004-02-10 Nostix Llc Ultrasound-guided near infrared spectrophotometer
US6711425B1 (en) 2002-05-28 2004-03-23 Ob Scientific, Inc. Pulse oximeter with calibration stabilization
JP4040913B2 (en) 2002-06-07 2008-01-30 株式会社パルメディカル Noninvasive arteriovenous oxygen saturation measuring device
US7024235B2 (en) 2002-06-20 2006-04-04 University Of Florida Research Foundation, Inc. Specially configured nasal pulse oximeter/photoplethysmography probes, and combined nasal probe/cannula, selectively with sampler for capnography, and covering sleeves for same
US6909912B2 (en) 2002-06-20 2005-06-21 University Of Florida Non-invasive perfusion monitor and system, specially configured oximeter probes, methods of using same, and covers for probes
AU2003242975B2 (en) 2002-07-15 2008-04-17 Itamar Medical Ltd. Body surface probe, apparatus and method for non-invasively detecting medical conditions
JP2004113353A (en) 2002-09-25 2004-04-15 Citizen Watch Co Ltd Blood analyzer
US7027849B2 (en) 2002-11-22 2006-04-11 Masimo Laboratories, Inc. Blood parameter measurement system
JP3944448B2 (en) 2002-12-18 2007-07-11 浜松ホトニクス株式会社 Blood measuring device
JP4284674B2 (en) 2003-01-31 2009-06-24 日本光電工業株式会社 Absorbent concentration measuring device in blood
US7272426B2 (en) 2003-02-05 2007-09-18 Koninklijke Philips Electronics N.V. Finger medical sensor
JP2004248819A (en) 2003-02-19 2004-09-09 Citizen Watch Co Ltd Blood analyzer
US8255029B2 (en) 2003-02-27 2012-08-28 Nellcor Puritan Bennett Llc Method of analyzing and processing signals
JP2004290545A (en) 2003-03-28 2004-10-21 Citizen Watch Co Ltd Blood analyzer
US6947780B2 (en) 2003-03-31 2005-09-20 Dolphin Medical, Inc. Auditory alarms for physiological data monitoring
KR100571811B1 (en) 2003-05-09 2006-04-17 삼성전자주식회사 Ear type measurement apparatus for bio signal
US7047056B2 (en) 2003-06-25 2006-05-16 Nellcor Puritan Bennett Incorporated Hat-based oximeter sensor
US8602986B2 (en) 2003-08-20 2013-12-10 Koninklijke Philips N.V. System and method for detecting signal artifacts
US7373193B2 (en) 2003-11-07 2008-05-13 Masimo Corporation Pulse oximetry data capture system
US20050113651A1 (en) 2003-11-26 2005-05-26 Confirma, Inc. Apparatus and method for surgical planning and treatment monitoring
WO2005074550A2 (en) 2004-01-30 2005-08-18 3Wave Optics, Llc Non-invasive blood component measurement system
CA2555807A1 (en) 2004-02-12 2005-08-25 Biopeak Corporation Non-invasive method and apparatus for determining a physiological parameter
US7277741B2 (en) 2004-03-09 2007-10-02 Nellcor Puritan Bennett Incorporated Pulse oximetry motion artifact rejection using near infrared absorption by water
US20050228248A1 (en) 2004-04-07 2005-10-13 Thomas Dietiker Clip-type sensor having integrated biasing and cushioning means
US20060025931A1 (en) 2004-07-30 2006-02-02 Richard Rosen Method and apparatus for real time predictive modeling for chronically ill patients
US7551950B2 (en) 2004-06-29 2009-06-23 O2 Medtech, Inc,. Optical apparatus and method of use for non-invasive tomographic scan of biological tissues
US7343186B2 (en) 2004-07-07 2008-03-11 Masimo Laboratories, Inc. Multi-wavelength physiological monitor
US7548771B2 (en) 2005-03-31 2009-06-16 Nellcor Puritan Bennett Llc Pulse oximetry sensor and technique for using the same on a distal region of a patient's digit
KR100716824B1 (en) 2005-04-28 2007-05-09 삼성전기주식회사 Printed circuit board with embedded capacitors using hybrid materials, and manufacturing process thereof
US8160668B2 (en) 2006-09-29 2012-04-17 Nellcor Puritan Bennett Llc Pathological condition detector using kernel methods and oximeters

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5630413A (en) * 1992-07-06 1997-05-20 Sandia Corporation Reliable noninvasive measurement of blood gases
US20060220881A1 (en) * 2005-03-01 2006-10-05 Ammar Al-Ali Noninvasive multi-parameter patient monitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kernel PLS regression on wavelet transformed NIR spectra for prediction of sugar content of apple Bart M. Nicolaï, Karen I. Theron, Jeroen Lammertyn, Chemometrics and Intelligent Laboratory Systems 85 (2007) 243-252 *
Lindgren et al. "The Kernel Algorithm for PLS" Journal of Chemometrics, Vol. 7, 45-59 (1993). *
Plastic identification by remote sensing spectroscopic NIR imaging using kernel partial least squares (KPLS) W.H.A.M. van den Broek, E.P.P.A. Derks E.W. van de Ven a D. Wienke P. Geladi b, L.M.C. Buydens Chemometrics and Intelligent Laboratory Systems 35 (1996) 187-197 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150103389A1 (en) * 2012-05-25 2015-04-16 View, Inc. Portable power supplies and portable controllers for smart windows

Also Published As

Publication number Publication date
US8292809B2 (en) 2012-10-23
US20090247844A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
US5842979A (en) Method and apparatus for improved photoplethysmographic monitoring of oxyhemoglobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin
JP5175179B2 (en) Improved blood oxygenation monitoring method by spectrophotometry
EP0850013B1 (en) Procedure for the determination of fractional oxygen saturation
US7884933B1 (en) Apparatus and method for determining analyte concentrations
JP6108498B2 (en) Method and apparatus for selecting a wavelength for optimal measurement of molecular analyte properties
Yamashita et al. Wavelength dependence of the precision of noninvasive optical measurement of oxy‐, deoxy‐, and total‐hemoglobin concentration
US6456862B2 (en) Method for non-invasive spectrophotometric blood oxygenation monitoring
US6441388B1 (en) Methods and apparatus for spectroscopic calibration model transfer
US5685301A (en) Apparatus for precise determination of operating characteristics of optical devices contained in a monitoring probe
KR100499139B1 (en) Method of removing abnormal data and blood constituent analysing system using spectroscopy employing the same
JP6019028B2 (en) System and method for optical measurement of blood parameters
US6927843B2 (en) Non-invasive measurement of skin bilirubin level
JP6878312B2 (en) Photoelectric volumetric pulse wave recording device
JP2000060826A (en) Noninvasive vital component measuring instrument
US20130324815A1 (en) Continuous measurement of total hemoglobin
JP2010088928A (en) Apparatus for non-invasively determining blood oxygen saturation level within tissue of subject, apparatus for calibrating near infrared spectrophotometric sensor, and apparatus for non-invasively determining oxyhemoglobin concentration and deoxyhemoglobin concentration within tissue of subject
US8923944B2 (en) Cancellation of light shunting
JP2002369814A (en) Noninvasive hemoglobin density and oxygen saturation degree monitoring method and device therefor
US20140073900A1 (en) System and method for measuring cardiac output
US20130024129A1 (en) Detecting chemical components from spectroscopic observations
US8840562B2 (en) Signal processing warping technique
US20090326347A1 (en) Synchronous Light Detection Utilizing CMOS/CCD Sensors For Oximetry Sensing
US20100076319A1 (en) Pathlength-Corrected Medical Spectroscopy
US8437822B2 (en) System and method for estimating blood analyte concentration
JP2004135798A (en) Substance measuring instrument

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION